InvestorsHub Logo

patientlywaiting

05/25/19 11:43 AM

#330471 RE: biopharm #330470

"Stafford left Xencor just for legal reasons to go after Peregrine?"

Actually Stafford left Xencor's BOD because he and other BOD members were sued by Xencor shareholders for cooking the Xencor books for their own personal gain. Just before a verdict was reached on the side of the Xencor shareholders he left.

https://www.strategicclaims.net/wp-content/uploads/2017/01/XencorNoticeClaim.pdf

Stafford's decision to leave prior to ruling against him and other Board members.

https://www.prnewswire.com/news-releases/xencor-announces-change-to-board-of-directors-300201814.html

And on to 2019. Stafford is at it again..........

Xencor Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider sale was by John Stafford for US$10.0m worth of shares, at about US$40.05 per share. So what is clear is that an insider saw fit to sell at around the current price of US$33.64. They might be selling for a variety of reasons, but it’s hard to argue this is a bullish sign. Arguably, insider selling at around current prices should give us reason to reflect on whether the stock is fully valued at the moment.

In the last twelve months insiders netted US$21m for 526.00k shares sold. Over the last year we saw more insider selling of Xencor shares, than buying. They sold for an average price of about US$40.26. We don’t gain much confidence from insider selling near the recent share price.

https://finance.yahoo.com/news/insiders-selling-xencor-inc-nasdaq-111200201.html